



The Manager
Company Announcements Office
Australian Stock Exchange
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

22 May 2020

Dear Sir or Madam

RE: APPENDIX 3Y – ANDREW WALSH – CEO & MANAGING DIRECTOR

Please find attached an Appendix 3Y announcement relating to the vesting of Deferred Share Rights and Performance Rights awarded in prior years to Andrew Walsh, CEO & Managing Director as well as the grant of Equity Rights and Performance Rights to Andrew Walsh as authorised at the AGM on 7 May 2020.

Yours sincerely

A handwritten signature in blue ink, appearing to be "PF", with a long horizontal line extending to the right.

Peter Ferguson
Group General Counsel & Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Iress Limited
ABN	47 060 313 359

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew Walsh
Date of last notice	25 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	21 May 2020

+ See chapter 19 for defined terms.

No. of securities held prior to change	<p>Ordinary Shares</p> <p>Direct: 361,805 Indirect: 44,909 406,714</p> <p><u>Unvested Share/Rights Grants Overview:</u></p> <p>Deferred Share Rights all Series: 142,018</p> <p>Performance Rights pre-2019 Series: 320,688</p> <p><u>Unvested Rights Grants under revised 2019 executive remuneration framework:</u></p> <p>Equity Rights: 80,020 Performance Rights: 80,020</p> <p><u>Unvested Share/Rights Grants Details:</u></p> <p>2016 Series Performance Rights 2016:</p> <ul style="list-style-type: none"> • 4 year term, granted 7 May 2016, 3 year measurement period commencing 1 Jan 2017: - 60,000 • 4 year term, granted 7 May 2016, 4 year measurement period commencing 1 Jan 2016: - 60,000 <p>2017 Series Deferred Shares Rights 2017:</p> <ul style="list-style-type: none"> • 3 year term: - 47,575 <p>Performance Rights 2017:</p> <ul style="list-style-type: none"> • 4 year term, 3 year measurement period commencing 1 Jan 2018: - 54,739 • 4 year term, 4 year measurement period commencing 1 Jan 2017: - 54,739 <p>2018 Series Deferred Shares Rights 2018:</p> <ul style="list-style-type: none"> • 3 year term, granted 10 May 2018: - 51,707 <p>Performance Rights 2018:</p> <ul style="list-style-type: none"> • 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: - 45,605 • 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: - 45,605 <p>2019 Series Deferred Shares Rights 2019:</p> <ul style="list-style-type: none"> • 3 year term, granted 9 May 2019: - 42,736 <p>2019 Series – New Framework Equity Rights 2019:</p> <ul style="list-style-type: none"> • 2 year term, granted 9 May 2019: - 80,020
---	--

+ See chapter 19 for defined terms.

	<p>Performance Rights 2019:</p> <ul style="list-style-type: none"> 3 year term, granted 9 May 2019: - 80,020 														
Class	Ordinary														
Number acquired	<p>Vesting of Deferred Share Rights 2017:</p> <ul style="list-style-type: none"> 3 year term granted May 2017: - 47,575 <p>Vesting of Performance Rights 2016:</p> <ul style="list-style-type: none"> 4 year term, 3 year measurement period granted May 2016: - 37,200* 4 year term, 4 year measurement period granted May 2016: - 48,000* <p>(*subject to November 2020 retest)</p> <p>Grant of Equity Rights 2020:</p> <ul style="list-style-type: none"> 2 year term, granted 21 May 2020: 76,374 <p>Grant of Performance Rights 2020:</p> <ul style="list-style-type: none"> 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020: 80,916 														
Number disposed	Nil														
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A														
No. of securities held after change	<p>Ordinary Shares</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Direct:</td> <td style="text-align: right;">494,580</td> </tr> <tr> <td>Indirect:</td> <td style="text-align: right;"><u>44,909</u></td> </tr> <tr> <td></td> <td style="text-align: right;">539,489</td> </tr> </table> <p><u>Unvested Share/Rights Grants Overview:</u></p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Deferred Share Rights all Series:</td> <td style="text-align: right;">94,443</td> </tr> <tr> <td>Performance Rights pre-2019 Series:</td> <td style="text-align: right;">235,488</td> </tr> </table> <p><u>Unvested Rights/Grants under revised 2019 executive remuneration framework:</u></p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Equity Rights:</td> <td style="text-align: right;">156,394</td> </tr> <tr> <td>Performance Rights:</td> <td style="text-align: right;">160,936</td> </tr> </table> <p><u>Unvested Share/Rights Grants Details:</u></p> <p>2016 Series subject to six month retest in Nov 2020 Performance Rights 2016:</p> <ul style="list-style-type: none"> 4 year term, granted May 2016, 3 year measurement period commencing 1 Jan 2017: - 22,800 	Direct:	494,580	Indirect:	<u>44,909</u>		539,489	Deferred Share Rights all Series:	94,443	Performance Rights pre-2019 Series:	235,488	Equity Rights:	156,394	Performance Rights:	160,936
Direct:	494,580														
Indirect:	<u>44,909</u>														
	539,489														
Deferred Share Rights all Series:	94,443														
Performance Rights pre-2019 Series:	235,488														
Equity Rights:	156,394														
Performance Rights:	160,936														

+ See chapter 19 for defined terms.

	<ul style="list-style-type: none"> • 4 year term, granted May 2016, 4 year measurement period commencing 1 Jan 2016: - 12,000 <p>2017 Series</p> <p>Performance Rights 2017:</p> <ul style="list-style-type: none"> • 4 year term, 3 year measurement period commencing 1 Jan 2018: - 54,739 • 4 year term, 4 year measurement period commencing 1 Jan 2017: - 54,739 <p>2018 Series</p> <p>Deferred Shares Rights 2018:</p> <ul style="list-style-type: none"> • 3 year term, granted 10 May 2018: - 51,707 <p>Performance Rights 2018:</p> <ul style="list-style-type: none"> • 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: - 45,605 • 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: - 45,605 <p>2019 Series</p> <p>Deferred Shares Rights 2019:</p> <ul style="list-style-type: none"> • 3 year term, granted 9 May 2019: - 42,736 <p>2019 Series – New Framework</p> <p>Equity Rights 2019:</p> <ul style="list-style-type: none"> • 2 year term, granted 9 May 2019: - 80,020 <p>Performance Rights 2019:</p> <ul style="list-style-type: none"> • 3 year term, granted 9 May 2019: – 80,020 <p>2020 Series – New Framework</p> <p>Equity Rights 2020:</p> <ul style="list-style-type: none"> • 2 year term, granted 21 May 2020, 2 year measurement period commencing 28 Feb 2020 – 28 Feb 2020, (shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 February 2022 – 28 February 2024)): – 76,374 <p>Performance Rights 2020:</p> <ul style="list-style-type: none"> • 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: – 80,916
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Vesting of 2017 Deferred Share Rights</p> <p>Partial vesting of 2016 Performance Rights</p> <p>Grants of 2020 Equity Rights and Performance Rights</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

+ See chapter 19 for defined terms.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.